Arvinas (ARVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 24, 2026, with voting on director elections, executive compensation, and auditor ratification.
Only shareholders of record as of April 27, 2026, are eligible to vote; 64,517,472 shares were outstanding as of that date.
Proxy materials are distributed electronically to reduce costs and environmental impact, with options for printed copies upon request.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class II directors for three-year terms, a non-binding advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
The board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by December 30, 2026, or nominate directors per advance notice bylaws.
Board of directors and corporate governance
The board is divided into three classes with staggered terms; after the meeting, it will have eight members.
Nominees for Class II are Leslie V. Norwalk, Esq. and Randy Teel, Ph.D.; Sunil Agarwal, M.D. is not standing for re-election.
The board has audit, compensation, nominating/governance, and science/technology committees, all with independent members except for the CEO.
Corporate governance guidelines, code of conduct, and insider trading policy are in place; annual board self-evaluations are conducted.
Latest events from Arvinas
- Votes will be held on director elections, executive pay, and auditor ratification at the 2026 meeting.ARVN
Proxy filing29 Apr 2026 - Improved financials and pipeline progress set stage for key 2026 milestones and FDA review.ARVN
Q4 20259 Apr 2026 - Phase I pipeline advances, vepdegestrant nears FDA decision, and key data readouts expected in 2024.ARVN
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024.ARVN
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple phase I programs advance with key data and commercialization milestones ahead.ARVN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Vepdegestrant shows strong clinical promise, with pivotal data and multiple launches expected by 2030.ARVN
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Vepdegestrant and CDK4/6 combos show strong efficacy, guiding future trial and regulatory strategies.ARVN
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Pivotal breast cancer data for vepdegestrant expected late 2024, with multiple launches planned.ARVN
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Phase III vepdegestrant data expected late 2024/early 2025, with broad pipeline progress.ARVN
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026